Big announcement on 05/14/2025: GSK Buys Liver-Disease Treatment From Boston Pharmaceuticals for up to $2 billion.
GSK plc is a British multinational pharmaceutical and biotechnology company with headquarters in London. The firm was stablished in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm.
Boston Pharmaceuticals’ Efimosfermin is in late-stage trials, with a potential market launch in 2029.
Efimosfermin, a monthly subcutaneous injection, is a phase III ready medicine to treat steatotic liver disease (SLD). It is also currently in clinical development for the treatment of MASH, a form of liver disease, characterized by inflammation and damage caused by build up of fat.
Full press release is here: https://www.gsk.com/en-gb/media/press-releases/gsk-to-acquire-efimosfermin-a-phase-iii-ready-potential-best-in-class-specialty-medicine-to-treat-and-prevent-progression-of-steatotic-liver-disease-sld/.